Stay updated on Nadunolimab Combo for Triple Negative Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Nadunolimab Combo for Triple Negative Breast Cancer Clinical Trial page.

Latest updates to the Nadunolimab Combo for Triple Negative Breast Cancer Clinical Trial page
- Check5 days agoChange DetectedThe study record now shows a Completed status, with the Primary Completion Date updated to 2026-04-09 and the Study Completion Date updated to 2026-05-08, replacing prior estimated dates. This change clarifies the final timeline of the trial.SummaryDifference0.4%

- Check12 days agoNo Change Detected
- Check20 days agoChange DetectedPage revision updated from v3.5.3 to v3.5.4, indicating a maintenance or content update to the Study Details page. The change does not modify the study data, results, or primary content presented.SummaryDifference0.0%

- Check26 days agoNo Change Detected
- Check41 days agoChange DetectedThe page’s footer revision label has been updated from **v3.5.2** to **v3.5.3**, indicating a minor site release without changing the displayed study record information.SummaryDifference0.0%

- Check48 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check55 days agoChange DetectedAdded new study details for Nadunolimab in combination with gemcitabine and carboplatin (TRIFOUR), including Phase Ib/II design and updated dates. Removed the prior TRIFOUR entry and related outdated notes.SummaryDifference0.4%

- Check77 days agoChange Detected- Revision: v3.5.0 added in the header; the previous version v3.4.3 was removed from the display.SummaryDifference0.0%

Stay in the know with updates to Nadunolimab Combo for Triple Negative Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nadunolimab Combo for Triple Negative Breast Cancer Clinical Trial page.